AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03003624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cautery tip
Description: Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
Study NCT03003624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP blade
Description: Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
Study NCT03434496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait Trainer 3
Description: With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
Study NCT03434496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Trainer 3
Description: With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
Study NCT02109601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive bedside training for accessing patient portal
Description: EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
Study NCT02109601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited bedside training on patient portal use.
Description: EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
Study NCT03862963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of diabetes care
Description: The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
Study NCT03862963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
Study NCT04059042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: Participants will have pain threshold testing while listening to silence, music, or nature sounds.
Study NCT04059042 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music Listening
Description: Participants will have pain threshold testing while listening to silence, music, or nature sounds.
Study NCT04255979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Study NCT03746613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEARO
Description: Robotic system for otological procedures
Study NCT04121546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecare Intervention
Description: Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
Study NCT00094861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study NCT04570462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia Via Cooling Machine- Arctic Sun 5000
Description: Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject.
Study NCT01735955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
Study NCT02382055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
Study NCT00787969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Give IV
Study NCT00787969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Description: Give IV
Study NCT00787969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Give IV
Study NCT00787969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Give SC
Study NCT00787969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT04169256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYR-PB21
Description: HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
Study NCT04169256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
Study NCT04169256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
Study NCT04169256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
Study NCT02755805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP
Study NCT02755805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Study NCT04024176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
Study NCT02316301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long interval misoprostol
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study NCT02316301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short interval misoprostol
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study NCT04816175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acquire Therapy
Description: This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
Study NCT01125254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5mg po for 12 months
Study NCT01125254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: 5mg po for 12 months
Study NCT03754036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep manipulation
Description: Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
Study NCT02382055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
Study NCT02382055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Behavioral Treatment
Description: Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
Study NCT02382055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Behavioral Treatment
Description: Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
Study NCT02845141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actifuse
Description: bone tunnel filled with Actifuse
Study NCT02845141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone graft
Description: bone graft to fill bone tunnel
Study NCT02556983 — intervention group
Intervention type: RADIATION
Intervention: CT
Description: Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
Study NCT02804711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
Study NCT02147691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33%
Description: Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
Study NCT02147691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.33%
Description: Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
Study NCT01548209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
Study NCT01548209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
Study NCT00723853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach-Out Program, nutritional and exercise program
Description: This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise.
Study NCT00723853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach-Out Program, nutritional and exercise program
Description: This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise.
Study NCT00723853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach-In Program, standard of care
Description: This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
Study NCT04116190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
Study NCT04116190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional inpatient rehabilitation
Description: Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
Study NCT03537183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: 12 weeks, 3 hours a week, moderate intensity exercise training
Study NCT02727504 — intervention group
Intervention type: DEVICE
Intervention: Electrocardiogram
Description: ECG at inclusion and M12
Study NCT02727504 — intervention group
Intervention type: DEVICE
Intervention: 2D and 3D echocardiography
Description: 2D and 3D echocardiography at inclusion and M12
Study NCT02727504 — intervention group
Intervention type: DEVICE
Intervention: Dobutamine stress echocardiography
Description: dobutamine stress echocardiography at inclusion
Study NCT02727504 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood tests
Description: Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
Study NCT02727504 — intervention group
Intervention type: DEVICE
Intervention: Cardiac MRI
Description: Cardiac MRI at inclusion
Study NCT02727504 — intervention group
Intervention type: DEVICE
Intervention: Cardiac scanner
Description: Cardiac scanner at inclusion
Study NCT02727504 — intervention group
Intervention type: OTHER
Intervention: 6-minutes walking test
Description: 6-minutes walking test at inclusion and M12
Study NCT02727504 — intervention group
Intervention type: OTHER
Intervention: Duke Activity Score
Description: Duke Activity Score at inclusion and M12
Study NCT02804711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
Study NCT05011331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedCline Shoulder Relief System
Description: Patients will receive a customized pillow to aid with sleep
Study NCT05011331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedCline Shoulder Relief System
Description: Patients will receive a customized pillow to aid with sleep
Study NCT02804711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
Study NCT02804711 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02804711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00718250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFUSIN2-AML1
Description: AML cell vaccine alone. x4 doses 3 weeks apart
Study NCT00718250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor leukocyte infusion (DLI)
Description: 1 dose 1x107/kg
Study NCT00718250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFUSIN2-AML1 and donor leukocyte infusion
Description: AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
Study NCT00718250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFUSIN2-AML1 and donor leukocyte infusion
Description: AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
Study NCT00804986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: Once weekly for 12 weeks as a subcutaneous injection.
Study NCT00912925 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rhIDU (recombinant human-Alpha-L-Iduronidase)
Description: Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
Study NCT00912925 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.